Related Experiment Video

Updated: Sep 23, 2025

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1
07:59

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1

Published on: December 5, 2020

2.7K

Therapeutic Strategies Focused on Cancer-Associated Hypercoagulation for Ovarian Clear Cell Carcinoma

Ryo Tamura1, Kosuke Yoshihara1, Takayuki Enomoto1

  • 1Department of Obstetrics and Gynecology, Niigata University Graduate School of Medical and Dental Sciences, Niigata 951-8510, Japan.

Cancers
|May 14, 2022
PubMed

Insights

Ovarian clear cell carcinoma (OCCC) shows high rates of blood clots due to specific molecular factors. Targeting hypercoagulation may offer new therapeutic strategies for this challenging cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Hematology

Background:

  • Ovarian clear cell carcinoma (OCCC) presents poor prognosis and chemotherapy resistance, particularly in advanced stages.
  • Genomic alterations like ARID1A and PIK3CA mutations are known in OCCC, but targeted therapies remain unconfirmed.
  • OCCC exhibits a high incidence of thromboembolism, linked to elevated tissue factor and interleukin-6 expression.

Purpose of the Study:

  • To review the molecular basis of cancer-associated hypercoagulation in OCCC.
  • To explore the potential of targeting hypercoagulation pathways for OCCC treatment.
  • To identify candidate drugs and therapeutic strategies for OCCC management.

Main Methods:

  • Literature review focusing on the association between hypercoagulation and OCCC molecular biology.
  • Analysis of OCCC-specific genetic alterations and their role in the tumor microenvironment.
  • Evaluation of potential therapeutic agents targeting hypercoagulation pathways.

Main Results:

  • OCCC is characterized by molecular factors promoting hypercoagulation, including tissue factor and interleukin-6.
  • Endometriosis-related tumor microenvironment may contribute to OCCC-associated hypercoagulation.
  • Candidate drugs include those targeting tissue factor, interleukin-6, anti-inflammatory agents, anti-hypoxia drugs, and anticoagulants.

Conclusions:

  • Hypercoagulation is a critical aspect of OCCC biology and clinical presentation.
  • Targeting hypercoagulation pathways presents a promising avenue for novel OCCC therapies.
  • Combined immunotherapy with hypercoagulation-targeting drugs warrants further investigation in OCCC.
Keywords:
D-dimerIL6cancer-associated thrombosishypoxiaimmunotherapyinflammationovarian clear cell carcinomatisotumab vedotintissue factor

More Related Videos

In vitro Enrichment of Ovarian Cancer Tumor-initiating Cells11:37

In vitro Enrichment of Ovarian Cancer Tumor-initiating Cells

Published on: February 18, 2015

13.9K
Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

12.4K

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
33
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
32
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
681
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K